600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Not Yet Opened 03-29 09:30:00
46.21
+0.00
0.00%
High
0.00
Low
0.00
Vol
0.00
Open
0.00
D1 Closing
46.21
Amplitude
0.00%
Mkt Cap
294.77B
Tradable Cap
294.77B
Total Shares
6.38B
T/O
0.00
T/O Rate
0.00%
Tradable Shares
6.38B
P/B
7.44
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Dow Jones · 03-15
Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk
Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk
Dow Jones · 2023-10-17
Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk
Load more
Introduction
Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、注射用甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、碘克沙醇注射液、酒石酸布托啡诺注射液、托伐普坦片、多西他赛注射液、厄贝沙坦片、注射用顺苯磺酸阿曲库铵。公司是国内最大的抗肿瘤药、手术用药和造影剂的研究和生产基地之一。公司产品涵盖了抗肿瘤药、手术麻醉类用药、特色输液、造影剂、心血管药等众多领域,已形成比较完善的产品布局,其中抗肿瘤、手术麻醉、造影剂等领域市场份额在行业内名列前茅。在全国医药工业信息年会发布的《2020年中国医药研发产品线最佳工业企业》榜单中,恒瑞医药位列榜首;在中国化学制药行业年度峰会上,公司荣获“2020中国化学制药行业工业企业综合实力百强”、“2020中国化学制药行业创新型优秀企业品牌”等多项荣誉。
Issue price:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd","latestPrice":46.21,"timestamp":1711674774000,"preClose":46.21,"halted":0,"volume":0,"delay":0,"floatShares":6379000000,"shares":6379000000,"eps":0.6595,"marketStatus":"Not Yet Opened","marketStatusCode":0,"change":0,"latestTime":"03-29 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.6595,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1711675800000},"adr":0,"adjPreClose":46.21,"symbolType":"stock","openAndCloseTimeList":[[1711675800000,1711683000000],[1711688400000,1711695600000]],"highLimit":50.83,"lowLimit":41.59,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"pbRate":7.44,"roa":"--","roe":"8.91%","epsLYR":0.61,"marketValue":294774000000,"floatMarketCap":294774000000,"peRate":70.068233,"changeRate":0,"turnoverRate":0,"status":2,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2024-04-02."},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2419916365","title":"Jiangsu Hengrui Medicine Earnings Growth May Continue to Accelerate -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2419916365","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2419916365?lang=en_us&edition=fundamental","pubTime":"2024-03-15 13:49","pubTimestamp":1710481740,"startTime":"0","endTime":"0","summary":"0549 GMT - Jiangsu Hengrui Medicine is likely to report strong earnings growth in 4Q 2023 and into 2024, helped by revenue recognition and sales pick up, Nomura analysts Jialin Zhang and Yi Xiang say in a research note. They expect Hengrui's 4Q sales to have grown 14.3% on a low base and continued growth of innovative drugs. Its 4Q gross profit margin likely improved by 0.3 percentage points to 84.1% on economies of scale and an increase in the proportion of high-margin innovative drugs, the analysts say. They raise Hengrui's 2023 and 2024 net profit forecasts by 3.2% and 11.6%, respectively. They increase the stock's target to CNY51.12 from CNY49.24 and maintain a neutral call. Shares last at CNY46.79. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2376173094","title":"Jiangsu Hengrui Medicine's 3Q Margins Likely Improved -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2376173094","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2376173094?lang=en_us&edition=fundamental","pubTime":"2023-10-17 11:13","pubTimestamp":1697512380,"startTime":"0","endTime":"0","summary":"0313 GMT - Jiangsu Hengrui Medicine is likely to report improvement in 3Q margins thanks to rising contribution from innovative drugs and selling expenses saved under the ongoing anticorruption campaign in China, Nomura analyst Jialin Zhang says in a research note. Zhang expects Hengrui's 3Q revenue to rise 5% on year on rising sales of innovative oncology drugs, partially offset by a relative high base last year. Nomura trims its 2023 and 2024 revenue forecasts by 0.5% and 0.6%, respectively, to factor in the ongoing anticorruption campaign's impact on revenue. Nomura maintains a neutral call on Hengrui but lowers its target price to CNY49.24 from CNY50.19 due to weaker revenue forecasts. Shares are last 1.0% lower at CNY43.74. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0932},{"period":"3month","weight":0.0217},{"period":"6month","weight":0.0283},{"period":"1year","weight":0.0744},{"period":"ytd","weight":0.0217}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"12727股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.012},{"period":"6month","weight":-0.0321},{"period":"1year","weight":-0.0708},{"period":"ytd","weight":0.012}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、注射用甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、碘克沙醇注射液、酒石酸布托啡诺注射液、托伐普坦片、多西他赛注射液、厄贝沙坦片、注射用顺苯磺酸阿曲库铵。公司是国内最大的抗肿瘤药、手术用药和造影剂的研究和生产基地之一。公司产品涵盖了抗肿瘤药、手术麻醉类用药、特色输液、造影剂、心血管药等众多领域,已形成比较完善的产品布局,其中抗肿瘤、手术麻醉、造影剂等领域市场份额在行业内名列前茅。在全国医药工业信息年会发布的《2020年中国医药研发产品线最佳工业企业》榜单中,恒瑞医药位列榜首;在中国化学制药行业年度峰会上,公司荣获“2020中国化学制药行业工业企业综合实力百强”、“2020中国化学制药行业创新型优秀企业品牌”等多项荣誉。","serverTime":1711674775745,"listedPrice":11.98,"stockholders":"501188人(较上一季度减少0.38%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}